ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Analyst Ratings Changes
PRQR has been the topic of a number of research reports. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target on the stock in a research note on Friday. HC Wainwright cut their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Cantor Fitzgerald lowered shares of ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Finally, Chardan Capital downgraded shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $5.00.
ProQR Therapeutics Stock Down 0.1 %
PRQR traded down $0.00 during trading on Tuesday, reaching $0.89. 10 shares of the stock were exchanged, compared to its average volume of 451,041. ProQR Therapeutics has a twelve month low of $0.53 and a twelve month high of $9.09. The stock's 50 day moving average price is $0.80 and its two-hundred day moving average price is $1.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93.